Search hospitals > Illinois > Carterville
SIH Cancer Institute
Claim this profileCarterville, Illinois 62918
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
174 reported clinical trials
1 medical researcher
Summary
SIH Cancer Institute is a medical facility located in Carterville, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Tumors, Adenocarcinoma and other specialties. SIH Cancer Institute is involved with conducting 174 clinical trials across 362 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Clinical Trials running at SIH Cancer Institute
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Bladder Carcinoma
Melanoma
Pancreatic Cancer
Cutaneous Melanoma
Gastric Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at SIH Cancer Institute?
SIH Cancer Institute is a medical facility located in Carterville, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Tumors, Adenocarcinoma and other specialties. SIH Cancer Institute is involved with conducting 174 clinical trials across 362 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.